422 related articles for article (PubMed ID: 29309569)
1. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
2. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
3. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
4. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
5. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.
Lübbers J; Rodríguez E; van Kooyk Y
Front Immunol; 2018; 9():2807. PubMed ID: 30581432
[TBL] [Abstract][Full Text] [Related]
7. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
8. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
9. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
[TBL] [Abstract][Full Text] [Related]
10. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
Gianchecchi E; Arena A; Fierabracci A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
[TBL] [Abstract][Full Text] [Related]
11. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Impact of Ketodeoxynonulosonic Acid in Host-Pathogen Interactions Using Uptake and Surface Display by Nontypeable Haemophilus influenzae.
Saha S; Coady A; Sasmal A; Kawanishi K; Choudhury B; Yu H; Sorensen RU; Inostroza J; Schoenhofen IC; Chen X; Münster-Kühnel A; Sato C; Kitajima K; Ram S; Nizet V; Varki A
mBio; 2021 Jan; 12(1):. PubMed ID: 33468699
[TBL] [Abstract][Full Text] [Related]
13. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.
Läubli H; Varki A
Cell Mol Life Sci; 2020 Feb; 77(4):593-605. PubMed ID: 31485715
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Siglec-sialic acid interactions in balancing immunological activation and tolerance during viral infections.
Saini P; Adeniji OS; Abdel-Mohsen M
EBioMedicine; 2022 Dec; 86():104354. PubMed ID: 36371982
[TBL] [Abstract][Full Text] [Related]
15. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.
Wielgat P; Rogowski K; Niemirowicz-Laskowska K; Car H
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575400
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
17. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
18. Targeting glyco-immune checkpoints for cancer therapy.
Manni M; Läubli H
Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
[No Abstract] [Full Text] [Related]
19. The therapeutic potential of sialylated Fc domains of human IgG.
Pleass RJ
MAbs; 2021; 13(1):1953220. PubMed ID: 34288809
[TBL] [Abstract][Full Text] [Related]
20. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
